A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes

C. R. De Farias, B. R. Cardoso, G. M.B. De Oliveira, I. C. De Mello Guazzelli, R. M. Catarino, M. C. Chammas, S. M.F. Cozzolino, M. Knobel

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)

Abstract

Purpose: To analyze the impact of selenium supplementation on serum antiTPO levels and thyroid echogenicity in patients with CAT, evaluating the response in subgroups with different GPx1 genotypes. Methods: CAT patients (n = 55) with positive antiTPO were randomized to selenomethionine (SeMet) 200 μg daily (n = 28) or placebo (n = 27) for 3 months. Assessments included GPx1 genotyping at baseline and serum levels of plasma selenium, erythrocyte GPx1 activity, antiTPO and thyroid echogenicity at baseline, and 3 and 6 months. Results: In the SeMet group, the increase in plasma levels of selenium and erythrocyte GPx1 activity was similar among patients with different GPx1 genotypes. In the overall cohort, patients randomized to SeMet showed a 5 % decrease in antiTPO levels at 3 months (p = non-significant) and 20 % at 6 months (p < 0.001 versus 3 months). In contrast, patients in the placebo group did not show significant changes in antiTPO levels at any time point. Subgroup analysis showed that patients with different GPx1 genotypes presented comparable responses in antiTPO levels and echogenicity index to SeMet. Conclusions: Selenium supplementation decreased serum antiTPO levels in CAT patients, with similar response among patients with different GPx1 genotypes.

Original languageEnglish
Pages (from-to)1065-1074
Number of pages10
JournalJournal of Endocrinological Investigation
Volume38
Issue number10
DOIs
Publication statusPublished - 23 Oct 2015
Externally publishedYes

Keywords

  • Autoimmunity
  • Genetic
  • Glutathione peroxidase GPx1
  • Polymorphism
  • Selenium
  • Thyroid gland

Cite this